Fig. 8: AR degraders suppresses antiandrogen resistance in PDOs.

A Representative brightfield images of MSK-PCa9 PDO treated with Veh (DMSO), ENZ (1 µM) or AC176 (16 nM) for 10 days. Scale bar represents 50 µm. B Bar plot represents the diameter measurement of MSK-PCa9 PDO treated with Veh (DMSO) (n = 6), ENZ (n = 6) or AC176 (n = 7). C Bar plot represents the cell number count of MSK-PCa9 PDO treated with Veh (DMSO), ENZ or AC176. n = 3 independently treated PDO cultures. D Representative brightfield images for MSK-PCa3 PDO treated with Veh (DMSO), ENZ (1 µM) or AC176 (16 nM) for 10 days. Scale bar represents 50 µm. E Bar plots represent the diameter measurement of MSK-PCa3 PDO treated with Veh (n = 6), ENZ (n = 6) or AC176 (n = 7). F Bar plot represents the cell number count of MSK-PCa3 PDO treated with Veh (DMSO), ENZ or AC176. n = 3 independently treated PDO cultures. For all panels unless otherwise noted, mean ± s.e.m. is presented, and p values were calculated using one-way ANOVA with Bonferroni multiple comparison test. G Schematic figure represents the hypothetic function of UBE2J1 as the bona fide E2 ubiquitin-conjugating enzyme for AR ubiquitination in PCa and how its frequent loss in PCa leads to resistance to antiandrogens. Schematic figure was created with BioRender.com.